Ibrutinib in previously treated Waldenström's macroglobulinemia.

By S. Treon, C. Tripsas, K. Meid, D. Warren, Gaurav Varma, R. Green, K. Argyropoulos, Guang Yang, Yanglin Cao, Lian Xu and 17 more. New England Journal of Medicine, 2015

875 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/856dd2dac4b09212302f6229f48e77ced60b9b11

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Simar Pal Singh
2. Floris Dammeijer
3. R. Hendriks

Citations in the corpus

• Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “It was subsequently demonstrated that Ibrutinib was also highly active and associated with durable responses in pretreated patients with Waldenström’s macroglobulinemia, whereby MYD88 and CXCR4 mutation status affected the response [188].”